Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Leona Cuttler

Biographic Data

ID5540565
NAMELeona Cuttler
GIVEN NAMESLeona
FAMILY NAMECuttler
SIGNATURECUTTLER L
AFFILIATIONSRainbow Babies & Children's Hospital
VERIFIEDNo
TOTAL WORKS4
TOTAL CITATIONS0
AUTHOR COUNT4
EDITOR COUNT0
FIRST PUBLICATION YEAR1998
LATEST PUBLICATION YEAR2016
H-INDEX0
  • To Prescribe or Not to Prescribe? Consumer Access to Life-Enhancing Products

    Detelina Marinova, Irina V Kozlenkova et al.•ARTICLE•Journal of Consumer Research•2016•References: 42

    With rapid biotechnological advances in specialty drugs and direct-to-consumer advertising, consumers are under tremendous pressure to look, perform, feel, and live better. This is often accomplished through the use of life-enhancing products, sometimes referred to as performance-enhancing products, which can be accessed only through a gatekeeper, such as a physician. Integrating consumer and medical research, this article investigates how physic…

  • Patient, Physician, and Consumer Drivers

    Leona Cuttler, Detelina Marinova et al.•ARTICLE•Medical Care•2009•References: 33

    BACKGROUND: Candidates for specialty drugs, the fastest growing and costliest pharmaceuticals, typically originate with primary care referrals. However, little is known about what drives such referrals-especially for large populations such as short, otherwise normal children (idiopathic short stature). Recent expanded approval of growth hormone (GH) makes more than 585,000 US children eligible for such treatment, potentially costing over $11 bill…

  • Physician Decisions to Discontinue Long-Term Medications Using a Two-Stage Framework

    Leona Cuttler, J B Silvers et al.•ARTICLE•Medical Care•2005•References: 29

    BACKGROUND: Physician decisions to discontinue prescription medications for chronic conditions are fundamental determinants of drug use but have been inadequately studied. The decision to stop growth hormone (GH) therapy is an important example because of high cost (approximately $26,000/y for a 48-kg child), complexity of treatment options, and expansion of patient populations. AIM: The aim of this study was to identify the factors that influenc…

  • Medical Decision-Making and the Patient

    Jagdip Singh, Leona Cuttler et al.•ARTICLE•Medical Care•1998•References: 13

    OBJECTIVES: This study examines two questions that relate to patients' role in medical decision making: (1) Do patients utilize multiple attributes in evaluating different treatment options?, and (2) Do patient treatment preferences evidence heterogeneity and disparate patterns? Although research has examined these questions by using either individual- or aggregate-level approaches, the authors demonstrate an intermediate level approach (ie, rela…

No prominent works on this page.

  • Medical Decision-Making and the Patient

    Jagdip Singh, Leona Cuttler et al.•ARTICLE•Medical Care•1998•References: 13

    OBJECTIVES: This study examines two questions that relate to patients' role in medical decision making: (1) Do patients utilize multiple attributes in evaluating different treatment options?, and (2) Do patient treatment preferences evidence heterogeneity and disparate patterns? Although research has examined these questions by using either individual- or aggregate-level approaches, the authors demonstrate an intermediate level approach (ie, rela…

  • Physician Decisions to Discontinue Long-Term Medications Using a Two-Stage Framework

    Leona Cuttler, J B Silvers et al.•ARTICLE•Medical Care•2005•References: 29

    BACKGROUND: Physician decisions to discontinue prescription medications for chronic conditions are fundamental determinants of drug use but have been inadequately studied. The decision to stop growth hormone (GH) therapy is an important example because of high cost (approximately $26,000/y for a 48-kg child), complexity of treatment options, and expansion of patient populations. AIM: The aim of this study was to identify the factors that influenc…

  • Patient, Physician, and Consumer Drivers

    Leona Cuttler, Detelina Marinova et al.•ARTICLE•Medical Care•2009•References: 33

    BACKGROUND: Candidates for specialty drugs, the fastest growing and costliest pharmaceuticals, typically originate with primary care referrals. However, little is known about what drives such referrals-especially for large populations such as short, otherwise normal children (idiopathic short stature). Recent expanded approval of growth hormone (GH) makes more than 585,000 US children eligible for such treatment, potentially costing over $11 bill…

  • To Prescribe or Not to Prescribe? Consumer Access to Life-Enhancing Products

    Detelina Marinova, Irina V Kozlenkova et al.•ARTICLE•Journal of Consumer Research•2016•References: 42

    With rapid biotechnological advances in specialty drugs and direct-to-consumer advertising, consumers are under tremendous pressure to look, perform, feel, and live better. This is often accomplished through the use of life-enhancing products, sometimes referred to as performance-enhancing products, which can be accessed only through a gatekeeper, such as a physician. Integrating consumer and medical research, this article investigates how physic…

Medicine (4 works) · Business (3 works) · Conjoint analysis (2 works) · Economics (2 works) · Family medicine (2 works) · Growth Hormone and Insulin-like Growth Factors (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Marketing (2 works) · Medical prescription (2 works) · Nursing (2 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae